New drug ALT001 tested for rare brain disorder
NCT ID NCT07476352
First seen Mar 24, 2026 · Last updated May 07, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug, ALT001, in 60 adults aged 30-75 with multiple system atrophy (MSA), a rare brain disease that affects movement and automatic body functions. The main goal is to check if the drug is safe and to see if it might help control symptoms. Participants will receive the drug and be monitored for side effects and changes in their condition over about 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
Conditions
Explore the condition pages connected to this study.